June 8, 2023

TB12 Co-Founded by Tom Brady and Alex Guerrero Will Offer Holistic Health and Wellness Options Focused on Performance and Recovery at Resort
LAS VEGAS, Sept. 12, 2022 /PRNewswire/ — Wynn Las Vegas announces a partnership with Tom Brady and Alex Guerrero’s TB12, a holistic health and wellness company modeled and inspired by the training regimen of the famed quarterback and his longtime Body Coach. TB12 is built on the TB12 Method, a series of healthy daily habits across five pillars: pliability, nutrition, hydration, movement, and mental fitness. The TB12 Method fully integrates these pillars, designed around muscle recovery and injury prevention to achieve longevity and pain-free living, through the help of solution-oriented Body Coach experts.
“After our successful collaboration with the Wynn for The Match back in June, it was a natural next step to make this partnership official on behalf of TB12,” said Tom Brady, TB12 co-founder. “Our TB12 Body Coaches who are the heart and soul of our business and experts in the field of health and wellness will be able to provide guests the exact blueprint of the work Alex and I have been doing together all these years. The addition of the TB12 experience to the Wynn’s already premium lineup of wellness-focused offerings is an incredible opportunity for our team to reach all guests looking to continue their health and wellness goals while traveling.”
Located within the Encore Fitness Center, the TB12 Body Coach sessions are grounded in innovative and personalized care, connecting guests one-on-one with training experts. The Body Coaches will develop a personalized treatment plan that incorporates the TB12 Method and each of the five pillars. In addition, nutritional snacks and TB12 smoothies and supplements will be available at Encore Juice Bar.
“TB12 is expanding rapidly in the marketplace and as we looked for a new partner on the West Coast, we knew the Wynn could bring forward an integrated wellness program for their visitors of all ages and level of activity,” said Grant Shriver, CEO of TB12.  “We’re thrilled to bring TB12 to the Vegas strip, activating at the highest level at one of the most prestigious resorts.”
The newest addition to the lineup of wellness-focused experiences at Wynn Las Vegas, TB12 Body Coach sessions join onsite amenities that include five-star spa services, an 18-hole golf course, and NutriDrip by Clean Market, among others.
“The introduction of TB12 signifies a fresh approach to wellness at our resort,” said Brian Gullbrants, President of Wynn Las Vegas. “Offering guests a way to maintain their wellness goals while on-the-go demonstrates our commitment to providing unique amenities not found anywhere else in Las Vegas.”
TB12 Body Coach sessions will occur at Wynn Las Vegas starting Sept. 22. Guests can book appointments as of today. Sessions are available to both visitors and guests of the resort. For more information, please visit www.WynnLasVegas.com.
About TB12
TB12 was founded by three-time NFL MVP and seven-time Super Bowl winning quarterback Tom Brady and his longtime Body Coach, Alex Guerrero. TB12’s mission is to empower anyone to love pain-free and perform their personal best, regardless of age or level of athleticism. The TB12 Method is modeled after the daily habits Tom uses to perform and recover at an elite level, and it is built on Alex’s theory that a holistic approach to health and wellness starts with pliability. The TB12 Method is a series of healthy daily habits across five pillars, facilitating muscle recovery, injury prevention, and improved performance for anyone with an active lifestyle. TB12 supports clients through an omni-channel approach that incorporates physical TB12 Center locations in Boston, Florida, Philadelphia, with more to come, immersive digital experiences, and innovative functional products. Information about TB12 products and services is available at TB12sports.com. To keep up with the latest TB12 news, please follow TB12 on Facebook (www.facebook.com/TB12sports), Instagram (www.instagram.com/TB12sports) and Twitter (https://twitter.com/TB12sports).
About Wynn Las Vegas
Wynn Resorts is the recipient of more Forbes Travel Guide Five Star Awards than any other independent hotel company in the world and in 2022 was once again honored on FORTUNE Magazine’s World’s Most Admired Companies list. Wynn and Encore Las Vegas consist of two luxury hotel towers with a total of 4,748 spacious hotel rooms, suites and villas. The resort features approximately 194,000 square feet of casino space, 21 signature dining experiences, 11 bars, two award-winning spas, approximately 513,000 rentable square feet of meeting and convention space, approximately 155,000 square feet of retail space as well as two showrooms, two nightclubs, a beach club, and recreation and leisure facilities, including Wynn Golf Club, an 18-hole, 129-acre championship golf course. For more information on Wynn and Encore Las Vegas, visit press.wynnlasvegas.com.
Media Contacts:
Jordan Massanari
Wynn Las Vegas
View original content to download multimedia:https://www.prnewswire.com/news-releases/wynn-las-vegas-launches-partnership-with-tb12-offering-onsite-body-coach-sessions-301622213.html
SOURCE Wynn Las Vegas
Related Quotes
A court judgment ostensibly about the leading Web2 company’s anti-competitive restrictions sends a warning to open-source developers whose software forks, CoinDesk was told.
Omeros Corp (NASDAQ: OMER) reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC). Narsoplimab showed the largest reduction in mortality risk to date across all drugs reported from the I-SPY COVID Trial. The company said that in approximately half of the patients died in the narsoplimab group, and narsoplimab was not given or was prematurely stopped, with those patients dying 9 to 35 days later. Omeros adds that despite narso
Lumakras had mixed results in a closely watched clinical trial comparing the drug to docetaxel. Analysts wonder if Mirati Therapeutics' drug will do better.
The following two healthcare stocks look like great buys for investors seeking to collect both above-average income and increase wealth. The good news for cancer patients is that Merck's (NYSE: MRK) cancer drug called Keytruda is approved in the U.S. to treat 19 different forms of the disease. Looking out over the long term, Merck's pipeline is just as strong as its existing products.
In Q2, HIV drugs generated more than two-thirds of its total revenue. If you delve further into the details, you'll see that two drugs — Biktarvy and, to a lesser extent, Descovy — appear to be cannibalizing sales of Gilead's other HIV drugs. Gilead is also partnering with Gritstone Bio to evaluate an experimental HIV therapeutic vaccine in an early-stage clinical study.
As the bear market emerged, even some of the healthiest companies saw their shares drop or stagnate. Shares of Axsome Therapeutics (NASDAQ: AXSM) have climbed 64% this year. Most of the gains came in recent weeks after the company's great news: It won U.S. regulatory approval for Auvelity, its drug for major depressive disorder (MDD).
Clovis (CLVS) files regulatory applications in the United States and Europe seeking label expansion for its sole marketed drug as a first-line maintenance treatment in advanced ovarian cancer.
Akero Therapeutics (AKRO) reports positive top-line data from a mid-stage study evaluating its lead candidate, efruxifermin (EFX), in patients with NASH, fibrosis stage 2 or 3 (F2-F3). Stock up.
Is Pfizer stock a sell on an expected decline for Covid vaccine sales in the third quarter? Is PFE stock now a sell?
There is little enthusiasm about coming study results for treatments targeting the protein amyloid beta, so there is upside for risk-seeking investors.
The FDA approval of Sotyktu for psoriasis has ignited and dampened prospects for smaller biotech stocks.
Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it has entered into a Commercial Services Agreement with Veru Inc. (Veru) for sabizabulin for COVID-19 in Canada. Sabizabulin is a novel dual antiviral and anti-inflammatory agent being targeted for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death.
By Gita Karunakaran, Benzinga
“Getting hit with a baseball bat once is better than getting hit five times,” one expert said.View Entire Post ›
FRANKFURT/LONDON (Reuters) -People in Europe should take whatever COVID-19 booster is available to them in the coming months, Emer Cooke, Executive Director of the European Medicines Agency (EMA), said in a Reuters Next Newsmaker interview ahead of an expected autumn rise in infections. Apart from the original COVID vaccines, the EMA has endorsed a number of Omicron-adapted vaccines in recent weeks. "The approach that we've taken in Europe is to have a plurality of options because we recognize that the needs in different member states may be different," she said, suggesting that countries will likely kick off their campaigns at different times or combine their rollouts with flu shots.
Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?
On the one hand, Sen. Ron Johnson argues that Social Security and Medicare should not be guaranteed but rather "negotiated" by Congress each year, leaving seniors with no sense of how much they can expect to receive the following year. On the other hand, a group of eight Democratic senators recently introduced legislation that would expand Social Security benefits by $2,400 a year. Rubio proposes a paid parental leave program that would force parents to take money out of their future Social Security earnings.
“The safety of the nation’s pharmaceutical supply is critically important,” said Principal Deputy Assistant Attorney General Brian M. Boynton, head of the Justice Department’s Civil Division
Experts told TODAY how walking can help with weight loss and shared some quick tips on how to make your workouts even more effective.
Lantern Pharma Inc (NASDAQ: LTRN) will present preclinical data on the in vivo efficacy of its drug candidate LP-184 for pancreatic cancer at the American Association for Cancer Research Special Conference. LP-184 is a small molecule drug candidate and next-generation acylfulvene that preferentially damages DNA in cancer cells harboring mutations in DNA damage repair (DDR) genes and overexpressing the enzyme PTGR1. Pancreatic cancer cells are expected to be sensitive to LP-184 treatment, as arou


Leave a Reply